MarketBeat rates Elevance Health stock Moderate Buy
Published on 10/06/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health (ISIN US0367521038) has a Moderate Buy consensus from 23 analysts and an average one-year target of USD 440.90, according to MarketBeat on October 6, 2026. The rating backdrop matters because the average target remains above the latest NYSE quote, while the company is preparing to report its third quarter.
Analysts weigh earnings recovery
Elevance Health reported second-quarter 2026 operating revenue of USD 49.83 billion and adjusted earnings per share of USD 7.45, according to Fortune on July 15, 2026. Revenue increased 0.80 percent year over year, while adjusted earnings exceeded the company outlook, giving investors a concrete basis for the revised full-year framework.
Management raised 2026 adjusted earnings guidance to at least USD 27.00 per diluted share and lifted operating cash flow guidance to at least USD 6.00 billion, as reported in the second-quarter transcript by Fortune. The comparison with the prior outlook is the key operating signal: earnings guidance moved higher even as Medicaid costs remained an important management issue.
Medicare plans add a second catalyst
On October 1, 2026, Elevance Health announced 2027 Medicare Advantage offerings with expanded coordination for dual-eligible members and additional chronic-condition plans, according to Business Wire. Medicare enrollment runs from October 15 through December 7, 2026, for coverage beginning January 1, 2027, creating a near-term test of plan demand and member mix.
The company also said its affiliated plans serve needs across Medicare and Medicaid, while its broader portfolio includes medical, pharmacy, behavioral and clinical services. That mix is relevant to the analyst view because the recovery case depends on more than one health benefits line.
Third-quarter date sets the next test
Elevance Health will release third-quarter 2026 results on October 21, 2026, at 6:00 a.m. EDT and hold its earnings call at 8:30 a.m. EDT, according to the Elevance Health release dated October 5, 2026. The report will show whether the USD 27.00 adjusted earnings target is supported by medical cost trends and membership performance.
On the NYSE, Elevance Health was trading at USD 396.11 on October 6, 2026 at 11:17 a.m. EDT. The quote stood within the 52-week range of USD 274.84 to USD 436.24, and the company had a market capitalization of USD 85.9 billion as of October 6, 2026.
Elevance Health stock facts
- Company: Elevance Health Inc.
- ISIN: US0367521038
- Ticker: ELV
- Primary exchange: NYSE
- Market capitalization: USD 85.9 billion (as of October 6, 2026)
- 52-week range: USD 274.84-436.24 (as of October 6, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: October 21, 2026
